• Our goal is to evaluate the effect of pre-treatment MRI on genitourinary (GU) and 
Introduction Patient Methods:
• We analyzed all 1085 patients (211 with MRI) who underwent definitive radiation treatment at our facility between January 01, 1999 and July 31, 2014
• We created two cohorts: 
Methods

Conclusions
•Pre-treatment MRI is associated with improved GU and GI toxicity outcomes in patients with localized prostate cancer
•Future prospective studies in a risk-matched cohort are needed to validate these findings
Background:
• MRI has certain advantages in patients with prostate cancer but is rarely ordered for localized disease
• The diagnostic abilities of MRI have been studied in prostate cancer but there is a lack of research on clinical outcomes
• We hypothesized that the improved tissue delineation with MRI would help to decrease radiation dose to healthy tissues and result in less GU and GI toxicity
Results
• MRI cohort had significantly more aggressive disease
• AUA scores returned to baseline more quickly in the MRI cohort (6 months) than the comparison cohort (12 months)
• RAS scores returned to baseline at 12 months in the MRI cohort, but never returned to baseline in the comparison cohort 
